Sinovac Receives Revised Approvals for Panflu

Extension of Eligible Age Group Enables Sinovac to Cover Larger Part of
Population

BEIJING, June 29 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
(NYSE Amex: SVA), a leading developer and provider of vaccines in China,
announced today that it has received a revised Drug Supplementary Application
Approval for Panflu(TM), Sinovac's pandemic influenza vaccine from the China
State Food and Drug Administration (SFDA), based on the Phase IIb clinical
trial, Under the revised approval, the age group eligible for use of the whole
viron inactivated pandemic influenza vaccine was expanded to 18 years old and
over, whereas it was previously 18 to 60 years of age, enabling Sinovac to
reach a much broader percentage of the population.
Sinovac also received a Supplementary Application Approval to change the
existing packaging of 0.5mL per vial of Panflu to 1mL per vial, which will
enable Sinovac to double its filling and packaging capacity.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
"Having received approval to administer our Panflu vaccines to individuals
over the age of 60, Sinovac now has the ability to protect a much larger
percentage of the Chinese population from pandemic influenza viruses. The
revised approval is especially important, as the 60+ age group is often a
high-risk group. We also now have the ability to supply a greater number of
vaccines, as the approval to increase the Panflu packaging to 1mL. We continue
to expect to complete production of the first batch of H1N1 Panflu vaccine by
the end of the July. With these revised approvals, Sinovac is better
positioned to deliver on its first order from the Beijing government, as well
as additional government orders we may receive in the future."
Sinovac is currently focused on production of a vaccine against the new
pandemic influenza strain, H1N1. This vaccine will be sold under the Panflu
brand, which has in the past also referred to Sinovac's vaccine against the
pandemic influenza strain, H5N1. Sinovac expects to complete production of
its first batch of the H1N1 Panflu vaccine by the end of July 2009.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's vaccine
products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and
B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine
(H5N1), has already been approved for government stockpiling. Sinovac is
developing vaccines for enterovirus 71, universal pandemic influenza, Japanese
encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary,
Tangshan Yian, is conducting field trials for independently developed
inactivated animal rabies vaccines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.
For more information, please contact:

Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com

Investors:
Amy Glynn/Sara Pellegrino
The Ruth Group
Tel: +1-646-536-7023/7002
Email: aglynn@theruthgroup.com
spellegrino@theruthgroup.com

Media:
Janine McCargo
The Ruth Group
Tel: +1-656-536-7033
Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.

Helen G. Yang, Sinovac Biotech Ltd. at +86-10-8289-0088 x9871, fax:
+86-10-6296-6910 or info@sinovac.com; Investors: Amy Glynn & Sara Pellegrino,
The Ruth Group at +1-646-536-7023 & 7002 or aglynn@theruthgroup.com &
spellegrino@theruthgroup.com; Media: Janine McCargo, The Ruth Group at
+1-656-536-7033 or jmccargo@theruthgroup.com